Prelude Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-89,097
| Closed | -$192K | – | 1504 |
|
|
2024
Q3 | $192K | Buy |
89,097
+48,800
| +121% | +$105K | 0.01% | 973 |
|
|
2024
Q2 | $208K | Buy |
+40,297
| New | +$208K | 0.01% | 896 |
|
|
2023
Q2 | – | Sell |
-14,899
| Closed | -$39.8K | – | 1305 |
|
|
2023
Q1 | $39.8K | Buy |
14,899
+500
| +3% | +$1.34K | ﹤0.01% | 918 |
|
|
2022
Q4 | $51.7K | Buy |
+14,399
| New | +$51.7K | ﹤0.01% | 985 |
|
|
2021
Q3 | – | Sell |
-1,420
| Closed | -$77K | – | 1789 |
|
|
2021
Q2 | $77K | Sell |
1,420
-40
| -3% | -$2.17K | ﹤0.01% | 1218 |
|
|
2021
Q1 | $109K | Buy |
1,460
+40
| +3% | +$2.99K | ﹤0.01% | 997 |
|
|
2020
Q4 | $154K | Sell |
1,420
-30
| -2% | -$3.25K | ﹤0.01% | 695 |
|
|
2020
Q3 | $128K | Buy |
1,450
+30
| +2% | +$2.65K | 0.01% | 617 |
|
|
2020
Q2 | $151K | Buy |
+1,420
| New | +$151K | 0.01% | 555 |
|
|
2019
Q3 | – | Sell |
-119
| Closed | -$11K | – | 1667 |
|
|
2019
Q2 | $11K | Buy |
+119
| New | +$11K | ﹤0.01% | 997 |
|
|
2018
Q3 | – | Sell |
-75
| Closed | -$8K | – | 1732 |
|
|
2018
Q2 | $8K | Buy |
+75
| New | +$8K | ﹤0.01% | 1233 |
|
|
2018
Q1 | – | Sell |
-49
| Closed | -$5K | – | 1602 |
|
|
2017
Q4 | $5K | Sell |
49
-26
| -35% | -$2.65K | ﹤0.01% | 1130 |
|
|
2017
Q3 | $11K | Sell |
75
-46
| -38% | -$6.75K | ﹤0.01% | 1294 |
|
|
2017
Q2 | $19K | Buy |
+121
| New | +$19K | ﹤0.01% | 1164 |
|